Praxis Precision Medicines Investor Relations Material

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company leverages genetic insights and a precision medicine approach to develop treatments for conditions such as epilepsy, movement disorders, and psychiatric conditions. Praxis is dedicated to addressing unmet medical needs through targeted therapies aimed at neurological circuits and pathways that are implicated in various CNS diseases. Its pipeline includes a range of investigational treatments designed to offer new therapeutic options for patients with these complex conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.